Niacin NCT06843148 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Not Applicable

Clinical phase

Recruiting

Recruitment status

36

Planned enrollment

2030-03-01

Primary-completion proxy

Executive view

NCT06843148 evaluates Niacin in Fibrosis, Liver. The disclosed sponsor is University of Sherbrooke, the design is Interventional, and the geographic footprint is Canada. The first listed primary endpoint is Prolonged small-dose niacin treatment does not lead to desensitization of the niacin-induced reduction in hepatic total fatty acids flux., assessed over Week 12, Week 28.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06843148 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Fibrosis, Liver landscape. Drug & Asset MCP drug_fetch was queried for Niacin, while Company & Deal Intelligence MCP organization_fetch was queried for University of Sherbrooke.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06843148	Niacin	Not Applicable / Recruiting	University of Sherbrooke	Canada	Prolonged small-dose niacin treatment does not lead to desensitization of the niacin-induced reduction in hepatic total… Week 12, Week 28	2030-03-01
NCT07214870	NNC-4005-0001	Phase 1 / Recruiting	Novo Nordisk A/S	Canada	Number of Treatment-emergent adverse event (TEAEs) From dosing (day 1) until compeletion of end of study (EOS) visit on…	2027-05-14
NCT07198386	CS-060380	Phase 2 / Recruiting	Cascade Pharmaceuticals, Inc.	China	MRI-PDFF D85	2026-07-24
NCT07185932	Rifaximin	Early Phase 1 / Recruiting	Shanghai Changzheng Hospital	China	The change in liver fat content measured by MRI at 24 weeks of treatment. From enrollment to the end of treatment at 24 weeks	2027-12-31
NCT07180745	Atorvastatin Calcium	Phase 4 / Not yet recruiting	Badr University In Cairo	Egypt	The controlled attenuation parameter (CAP). After 3 months	2026-02-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06843148 is a Not Applicable, recruiting study with 36 planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Crossover Assignment.

The primary endpoint is “Prolonged small-dose niacin treatment does not lead to desensitization of the niacin-induced reduction in hepatic total fatty acids flux.” over “Week 12, Week 28.” The retrieved endpoint description is: Total 6 h integrated uptake of circulating NEFAs, DFAs, and all FAs in liver: represents the sum of the rate of NEFA uptake integrated over 360 min for the entire organ and the rate of DFA uptake integrated over 360 min for the entire organ..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 36 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Fibrosis, Liver. These records do not establish direct evidence for NCT06843148 unless the registration number matches.

A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhib…

Phase 2; n=39; Absolute Change in HbA1c(Least Squares Mean) = 0.16 percentage of glycosylated hemoglobin (95% Confidence Interval, -0.32 to 0.63); Absolute Change in HbA1c(Least Squares Mean) = -1.11 percentage of glycosylated hemoglobin (95% Confidence Interval, -1.6 to -0.62) Source: https://clinicaltrials.gov/ct2/show/results/NCT05232071

Role of Lisinopril in Preventing The Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD

Phase 2; n=35; Pre-Treatment(Mean) = 48 ng/mL (Standard Deviation, 17) Source: https://clinicaltrials.gov/ct2/show/results/NCT04550481

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steato…

Phase 2; n=213; ADR = 10 Participants ; ADR = 8 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05039450

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Niacin is indexed as Small molecule drug with HCAR3 x NIACR1 biology and a global stage of Approved. The asset profile lists Astellas Pharma, Inc. as an originator or developer.

University of Sherbrooke is indexed in Canada with the website https://www.usherbrooke.ca. University of Sherbrooke is a large public French-language university that provides higher education courses and programs. The record lists 15 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Niacin is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06843148
Protocol source: https://clinicaltrials.gov/study/NCT06843148
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Niacin in Fibrosis, Liver is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Prolonged small-dose niacin treatment does not lead to desensitization of the niacin-induced reduction in hepatic total fatty acids flux. and 2030-03-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP